Bio-Rad Laboratories, Inc. (BIO) Holdings Decreased by Northern Trust Corp

Northern Trust Corp decreased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 21.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 214,472 shares of the medical research company’s stock after selling 58,739 shares during the quarter. Northern Trust Corp owned about 0.72% of Bio-Rad Laboratories worth $48,537,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Northwestern Mutual Investment Management Company LLC increased its position in shares of Bio-Rad Laboratories by 0.4% during the 2nd quarter. Northwestern Mutual Investment Management Company LLC now owns 3,596 shares of the medical research company’s stock worth $514,000 after purchasing an additional 13 shares during the last quarter. World Asset Management Inc increased its position in shares of Bio-Rad Laboratories by 1.4% during the 2nd quarter. World Asset Management Inc now owns 1,025 shares of the medical research company’s stock worth $232,000 after purchasing an additional 14 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Bio-Rad Laboratories by 1.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock worth $377,000 after purchasing an additional 29 shares during the last quarter. US Bancorp DE increased its position in shares of Bio-Rad Laboratories by 0.8% during the 2nd quarter. US Bancorp DE now owns 4,224 shares of the medical research company’s stock worth $956,000 after purchasing an additional 34 shares during the last quarter. Finally, State of Wisconsin Investment Board increased its position in shares of Bio-Rad Laboratories by 1.0% during the 2nd quarter. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company’s stock worth $948,000 after purchasing an additional 40 shares during the last quarter. 62.84% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Michael Crowley sold 700 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the completion of the sale, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 28.29% of the company’s stock.

WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/09/bio-rad-laboratories-inc-bio-holdings-decreased-by-northern-trust-corp.html.

Bio-Rad Laboratories, Inc. (BIO) opened at 226.26 on Monday. The stock’s 50 day moving average price is $221.47 and its 200 day moving average price is $220.14. The company has a market capitalization of $6.71 billion, a P/E ratio of 447.15 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 52 week low of $154.89 and a 52 week high of $242.79.

Several research analysts have weighed in on BIO shares. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Deutsche Bank AG reaffirmed a “buy” rating and set a $255.00 price target on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target on the stock. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Jeffer

Several other large investors also recently bought and sold shares of the business. Northwestern Mutual Investment Management Company LLC increased its position in shares of Bio-Rad Laboratories by 0.4% during the 2nd quarter. Northwestern Mutual Investment Management Company LLC now owns 3,596 shares of the medical research company’s stock worth $514,000 after purchasing an additional 13 shares during the last quarter. World Asset Management Inc increased its position in shares of Bio-Rad Laboratories by 1.4% during the 2nd quarter. World Asset Management Inc now owns 1,025 shares of the medical research company’s stock worth $232,000 after purchasing an additional 14 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Bio-Rad Laboratories by 1.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock worth $377,000 after purchasing an additional 29 shares during the last quarter. US Bancorp DE increased its position in shares of Bio-Rad Laboratories by 0.8% during the 2nd quarter. US Bancorp DE now owns 4,224 shares of the medical research company’s stock worth $956,000 after purchasing an additional 34 shares during the last quarter. Finally, State of Wisconsin Investment Board increased its position in shares of Bio-Rad Laboratories by 1.0% during the 2nd quarter. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company’s stock worth $948,000 after purchasing an additional 40 shares during the last quarter. 62.84% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Michael Crowley sold 700 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the completion of the sale, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 28.29% of the company’s stock.

WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/09/bio-rad-laboratories-inc-bio-holdings-decreased-by-northern-trust-corp.html.

Bio-Rad Laboratories, Inc. (BIO) opened at 226.26 on Monday. The stock’s 50 day moving average price is $221.47 and its 200 day moving average price is $220.14. The company has a market capitalization of $6.71 billion, a P/E ratio of 447.15 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 52 week low of $154.89 and a 52 week high of $242.79.

Several research analysts have weighed in on BIO shares. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Deutsche Bank AG reaffirmed a “buy” rating and set a $255.00 price target on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target on the stock. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $240.00.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply